|
1
|
Dawson SJ, Provenzano E and Caldas C:
Triple negative breast cancers: Clinical and prognostic
implications. Eur J Cancer. 45:27–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murai J, Huang SYN, Das BB, Renaud A,
Zhang Y, Doroshow JH, Ji J, Takeda S and Pommier Y: Trapping of
PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res.
72:5588–5599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rouleau M, Patel A, Hendzel MJ, Kaufmann
SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev
Cancer. 10:293–301. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gopal AK, Kahl BS, de Vos S,
Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR,
Martin P, Viardot A, et al: PI3Kδ inhibition by idelalisib in
patients with relapsed indolent lymphoma. N Engl J Med.
370:1008–1018. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burger MT, Pecchi S, Wagman A, Ni ZJ,
Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S,
et al: Identification of NVP-BKM120 as a potent, selective, orally
bioavailable class I PI3 kinase inhibitor for treating cancer. ACS
Med Chem Lett. 2:774–779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maira SM, Pecchi S, Huang A, Burger M,
Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al:
Identification and characterization of NVP-BKM120, an orally
available pan-class I PI3-kinase inhibitor. Mol Cancer Ther.
11:317–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brachmann SM, Kleylein-Sohn J, Gaulis S,
Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger
M, Stauffer F, Vaxelaire J, et al: Characterization of the
mechanism of action of the pan class I PI3K inhibitor NVP-BKM120
across a broad range of concentrations. Mol Cancer Ther.
11:1747–1757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Juvekar A, Burga LN, Hu H, Lunsford EP,
Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis
CA, et al: Combining a PI3K inhibitor with a PARP inhibitor
provides an effective therapy for BRCA1-related breast cancer.
Cancer Discov. 2:1048–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matulonis U, Wulf GM, Birrer MJ, Westin
SN, Farooq S, Bell-McGuin KM, Obermayer E, Whalen C, Spagnoletti T,
Luo W, et al: Phase I study of oral BKM120 and oral olaparib for
high-grade serous ovarian cancer (HGSC) or triple-negative breast
cancer (TNBC). Ann Oncol. 28:512–518. 2017.PubMed/NCBI
|
|
12
|
Isakoff SJ, Mayer EL, He L, Traina TA,
Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, et al:
TBCRC009: A multicenter phase II clinical trial of platinum
monotherapy with biomarker assessment in metastatic triple-negative
breast cancer. J Clin Oncol. 33:1902–1909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weichselbaum RR, Ishwaran H, Yoon T,
Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike
B, et al: An interferon-related gene signature for DNA damage
resistance is a predictive marker for chemotherapy and radiation
for breast cancer. Proc Natl Acad Sci USA. 105:18490–18495. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Daley JM and Sung P: 53BP1, BRCA1, and the
choice between recombination and end joining at DNA double-strand
breaks. Mol Cell Biol. 34:1380–1388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Donovan PJ and Livingston DM: BRCA1 and
BRCA2: Breast/ovarian cancer susceptibility gene products and
participants in DNA double-strand break repair. Carcinogenesis.
31:961–967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J,
Zhi X and Zhang J: Effects of PI3K inhibitor NVP-BKM120 on
overcoming drug resistance and eliminating cancer stem cells in
human breast cancer cells. Cell Death Dis. 6:e20202015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu Y, Qiu Y, Yague E, Ji W, Liu J and
Zhang J: miRNA-205 targets VEGFA and FGF2 and regulates resistance
to chemotherapeutics in breast cancer. Cell Death Dis. 7:e22912016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Modesti M and Kanaar R: DNA repair:
Spot(light)s on chromatin. Curr Biol. 11:R229–R232. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baumann P and West SC: Role of the human
RAD51 protein in homologous recombination and double-stranded-break
repair. Trends Biochem Sci. 23:247–251. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lundin C, Schultz N, Arnaudeau C, Mohindra
A, Hansen LT and Helleday T: RAD51 is involved in repair of damage
associated with DNA replication in mammalian cells. J Mol Biol.
328:521–535. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang L, Graham PH, Hao J, Ni J, Bucci J,
Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors
enhance radiosensitivity in radioresistant prostate cancer cells
through inducing apoptosis, reducing autophagy, suppressing NHEJ
and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tung NM and Garber JE: BRCA1/2 testing:
Therapeutic implications for breast cancer management. Br J Cancer.
119:141–152. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abramson VG, Lehmann BD, Ballinger TJ and
Pietenpol JA: Subtyping of triple-negative breast cancer:
Implications for therapy. Cancer. 121:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang L, Liu Q, Chen S and Shao Z:
Cisplatin versus carboplatin in combination with paclitaxel as
neoadjuvant regimen for triple negative breast cancer. OncoTargets
Ther. 10:5739–5744. 2017. View Article : Google Scholar
|
|
26
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Podo F, Buydens LMC, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: Triple-negative breast cancer: Present challenges
and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JM, Hays JL, Annunziata CM, Noonan AM,
Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD,
et al: Phase I/Ib Study of olaparib and carboplatin in BRCA1 or
BRCA2 mutation-associated breast or ovarian cancer with biomarker
analyses. J Natl Cancer Inst. 106:dju0892014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Robertson L, Hanson H, Seal S,
Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley
S, Butler S, et al: BRCA1 testing should be offered to individuals
with triple-negative breast cancer diagnosed below 50 years. Br J
Cancer. 106:1234–1238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Juvekar A, Hu H, Yadegarynia S, Lyssiotis
CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, et al:
Phosphoinositide 3-kinase inhibitors induce DNA damage through
nucleoside depletion. Proc Natl Acad Sci USA. 113:E4338–E4347.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JM, Hays JL, Chiou VL, Annunziata CM,
Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, et al:
Phase I/Ib study of olaparib and carboplatin in women with triple
negative breast cancer. Oncotarget. 8:79175–79187. 2017.PubMed/NCBI
|
|
32
|
Zhang L, Reyes A and Wang X: The Role of
DNA repair in maintaining mitochondrial DNA stability. Adv Exp Med
Biol. 1038:85–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma A and Dai X: The relationship between
DNA single-stranded damage response and double-stranded damage
response. Cell Cycle. 17:73–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee JM, Ledermann JA and Kohn EC: PARP
Inhibitors for BRCA1/2 mutation-associated and BRCA-like
malignancies. Ann Oncol. 25:32–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Domagala P, Huzarski T, Lubinski J, Gugala
K and Domagala W: PARP-1 expression in breast cancer including
BRCA1-associated, triple negative and basal-like tumors: Possible
implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat.
127:861–869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ossovskaya V, Koo IC, Kaldjian EP, Alvares
C and Sherman BM: Upregulation of poly (ADP-ribose) polymerase-1
(PARP1) in triple-negative breast cancer and other primary human
tumor types. Genes Cancer. 1:812–821. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ayub A, Yip WK and Seow HF: Dual
treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to
inhibit cell growth, induce apoptosis, and arrest cell cycle at G1
phase in MDA-MB-231 cell line. Biomed Pharmacother. 75:40–50. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ibrahim YH, García-García C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
